8-K: Tyra Biosciences Initiates Phase 2 Clinical Study for Bladder Cancer Drug TYRA-300, Updates Pediatric Achondroplasia Timeline

Tyra Biosciences, Inc. announced the dosing of the first patient in its Phase 2 clinical study (SURF302) for TYRA-300 in bladder cancer, while also updating the timeline for its pediatric achondroplasia study (BEACH301).

Summary

• Tyra Biosciences, Inc. has dosed the first patient in its SURF302 Phase 2 clinical study for TYRA-300.
• The SURF302 study evaluates TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC) with FGFR3 alterations.
• The study is open-label, will enroll up to 90 participants primarily in the United States, and will randomize patients to 50 mg once daily or 60 mg once daily dosing.
• The primary endpoint for SURF302 is the complete response (CR) rate at three months, with initial data expected in the first half of 2026.
• TYRA-300 is also being evaluated in the BEACH301 Phase 2 study for pediatric achondroplasia, which is open for enrollment.
• First child dosing for the BEACH301 study is now expected in the second half of 2025.

Sentiment

Score: 7

Explanation: The initiation of a Phase 2 study is a positive development, indicating pipeline progression. However, the slight delay in the pediatric achondroplasia study and the inherent risks of clinical trials temper the overall sentiment. The focus on unmet medical needs and targeted therapies is positive.

Positives

• Initiation of the SURF302 Phase 2 clinical study for TYRA-300 in bladder cancer marks a significant advancement in the drug's development.
• The SURF302 study design includes two initial dosing cohorts (50 mg QD and 60 mg QD), allowing for evaluation of optimal dosage.
• The BEACH301 Phase 2 study for pediatric achondroplasia is open for enrollment, indicating continued progress in another key indication.

Risks

• Potential for delays in the commencement, recruitment, enrollment, data readouts, and completion of clinical trials and preclinical studies.
• Results from preclinical studies or early clinical trials may not be predictive of future results.
• Interim results of a clinical trial are not necessarily indicative of final results, and clinical outcomes may materially change as patient enrollment continues or more data becomes available.
• Unconfirmed responses in clinical trials may not ultimately result in confirmed responses to treatment.
• Proof-of-concept results may fail to lead to successful subsequent development of TYRA-300.
• Later developments with the U.S. Food and Drug Administration (FDA) may be inconsistent with prior feedback.
• Dependence on third parties for manufacturing, research, and preclinical testing.
• Risk of unexpected adverse side effects or inadequate efficacy of product candidates, which could limit development, regulatory approval, and/or commercialization.
• Potential for programs and prospects to be negatively impacted by developments relating to competitors, including study results or regulatory determinations.
• Regulatory developments in the United States and foreign countries could impact the company's operations.

Future Outlook

Tyra Biosciences expects to report initial three-month complete response data from the SURF302 study in the first half of 2026. The company also anticipates the first child dosing in the BEACH301 Phase 2 study for pediatric achondroplasia in the second half of 2025.

Management Comments

• Tyra Biosciences, Inc. announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
• The Company expects to report initial three-month CR data in the first half of 2026.
• The Company now expects first child dosing in the second half of 2025 for the BEACH301 Phase 2 study.

Industry Context

This announcement positions Tyra Biosciences as an active player in the targeted oncology and rare disease therapeutic areas, specifically addressing FGFR3-altered cancers and achondroplasia. The initiation of a Phase 2 study for bladder cancer and continued progress in pediatric achondroplasia demonstrate the company's commitment to advancing its pipeline, aligning with broader industry trends of precision medicine and addressing unmet medical needs.

Stakeholder Impact

• Shareholders: Potential for increased valuation if clinical trials are successful, but also risk of dilution or stock price decline if trials fail or are significantly delayed.
• Patients (Bladder Cancer): Potential for a new treatment option for low-grade, intermediate risk non-muscle invasive bladder cancer with FGFR3 alterations.
• Patients (Pediatric Achondroplasia): Potential for a new treatment option for children with achondroplasia.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Regulatory Authorities (FDA): Ongoing engagement and review of clinical trial data for potential future approvals.

Next Steps

• Continue enrollment for the SURF302 Phase 2 clinical study (up to 90 participants).
• Potentially evaluate an additional dosing cohort for SURF302 after initial efficacy and safety review.
• Report initial three-month complete response (CR) data from SURF302 in the first half of 2026.
• Achieve first child dosing in the BEACH301 Phase 2 study for pediatric achondroplasia in the second half of 2025.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA-300, Bladder Cancer, NMIBC, Achondroplasia, Clinical Trial, Phase 2, Oncology, Rare Disease, Biotechnology, FGFR3